Our Difference is the Science
Fueling Our Pipeline
The scientists of Ymmunobio are innovating cancer treatment with novel therapeutic antibodies. Our science is focused on novel and first-in-class NPTXR antibodies and CEACAM1 immune agonistic antibodies.
Through robust scientific data and strong IP, we have been able to design antibodies that enable CEACAM1 to act as a checkpoint inhibitor and, most importantly, have a direct co-stimulatory effect on immune cells.
Our first-in-class NPTXR antibodies directly target various cancers overexpressing NPTXR and selectively kill cancer cells so that healthy tissue is not affected.
Our main differentiator is the dual action of our antibodies, in addition to a significant set of in vitro and in vivo data. Ymmunobio’s scientists are advancing research into NPTXR and CEACAM1.
CEACAM1
We are currently investigating several CEACAM1/5 antibodies for their broad applicability in solid tumors. Our research targets cell-to-cell communication, in order to promote an increase in efficiency of the immune response to tumor cells.
YB-200
Our dual action lead asset overcomes resistance by directly co-stimulating immune cells. We were able to design antibodies that leverage both aspects of the CEACAM1 physiological but also its pathophysiological role.
Along with instigating cell-to-cell communication, the antibody can also act as a checkpoint inhibitor disrupting the interaction of CEACAM1 on tumor and immune cells. Indications include hepatocellular carcinoma, colon cancer and melanoma. The FDA has granted YB-200 Orphan Drug Designation (ODD) for the treatment of hepatocellullar carcinoma.
Metastatic colorectal cancer
44%
Less than 50% of patients respond to current immune therapy
NPTXR
Our research into Neuronal Pentraxin Receptors (NPTXR) is focused on its development as a first-in-class monoclonal antibody against tumor markers in GI cancers. The antibody is able to “switch on” apoptosis selectively, and healthy tissue is not affected.
YB-800
Our first–in-class antibody for gastrointestinal tumors is a new target that was discovered through analyses of a large tumor bank.
YB-800 is a molecular target therapeutic drug containing a substance that neutralizes or inhibits expression of Neuronal pentraxin receptor (NPTXR) as an active ingredient. Indications for this therapy include stomach cancer, colorectal cancer, breast cancer, lung cancer, pancreatic cancer, or esophageal cancer.
LEAD INDICATION: COLON CANCER
3rd
Most common cancer globally
2nd
Most deadly cancer
SECONDARY INDICATION: GASTRIC CANCER
5th
Most common cancer globally
3rd
Most deadly cancer